Assessment of Modeling Strategies for Lightly Reinforced Concrete Shear Walls

element detailing, which suggest they are susceptible to brittle, compression-controlled failure modes, and deemed deficient by industry practitioners. Researchers at the California Polytechnic State University [1], San Luis Obispo (Cal Poly), recently tested a slender RC wall with vertical and horizontal reinforcement ratios approaching ACI 318-14 [2] code minimum (ρl= ρh= 0.37%) and no boundary elements. Results from this wall test will be presented and contrasted with a set of lightly reinforced walls, specimens C1-C3 tested by Lu et al. [3] at the University of Auckland, New Zealand, with higher levels of reinforcement (ρl= 0.53%). This paper will examine the Cal Poly and Lu et al. walls by comparing experimental test results. It will also comment on the accuracy of current modelling strategies used by industry practitioners to estimate the strength, stiffness, and ductility of existing lightly reinforced walls. Finally, it will make recommendations for the necessary model calibrations to achieve accurate prediction of the response of the lightly reinforced walls using PERFORM-3D [4], as a refinement of Lowes et al. [5] modeling recommendations for this wall type. The overall goal with this study is to facilitate accurate modeling that will provide detailed understanding of the wall response, and to inform the industry practitioner about the need for retrofitting to meet modern standards

Passive noise control strategies for jets exhausting over flat surfaces : an LES study

Unconventional aircraft propulsion configurations have to be considered in the future to address environmental issues, including air traffic noise that is know to affect communities surrounding airports. One approach involves rectangular jets in the vicinity of flat surfaces that are parallel to the jet axis in an attempt to shield the noise, but previous experimental work indicated that there is an increase in the noise generated by these configurations, mainly associated with the effect that the plate trailing edge exerts on the flow. In this work, we use large eddy simulations to investigate the potential of wall deformations at the plate trailing edge to reduce jet noise. We consider a high aspect ratio rectangular nozzle exhausting a jet over a flat surface in different configurations, and estimate the farfield noise using the Ffowcs Williams and Hawkins acoustic analogy. Because of the high aspect ratio of the rectangular nozzle, we approximate the jet as being two-dimensional, and use periodic boundary conditions in the spanwise direction. For the configurations that we considered here, the trailing edge deformations did not seem to affect the noise significantly; an overall sound pressure level in the order of 1-2 dB was observed for some selected cases

Simulation of Single and Twin Impinging Jets in Cross-flow of VTOL Aircrafts (Review)

When operating near the ground beneath a Vertical/Short Take-Off and Landing (VSTOL) aircraft a complex turbulent 3D flow is generated. This flow field can be represented by the configuration of twin impinging jets in a cross-flow. Studying these jets is a significant parameter for the design of VTOL aircraft. This flowfield during very low speed or hover flight operations is very complex and time dependent. An important number of experimental researches and simulations have been carried out to be able to understand much better these flows related with powered lift vehicles. Computational Fluid Dynamics (CFD) approach will be used in this paper work for simulation purposes of a single and twin impinging jet through and without crossflow

The role of viral and bacterial infections in the pathogenesis of IPF: a systematic review and meta-analysis

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Several risk factors such as smoking, air pollution, inhaled toxins, high body mass index and infectious agents are involved in the pathogenesis of IPF. In the present study, this meta-analysis study investigates the prevalence of viral and bacterial infections in the IPF patients and any possible association between these infections with pathogenesis of IPF. Methods: The authors carried out this systematic literature review from different reliable databases such as PubMed, ISI Web of Science, Scopus and Google Scholar to December 2020.Keywords used were the following �Idiopathic pulmonary fibrosis�, �Infection�, �Bacterial Infection� and �Viral Infection�, alone or combined together with the Boolean operators "OR�, �AND� and �NOT� in the Title/Abstract/Keywords field. Pooled proportion and its 95 CI were used to assess the prevalence of viral and bacterial infections in the IPF patients. Results: In this systematic review and meta-analyses, 32 studies were selected based on the exclusion/inclusion criteria. Geographical distribution of included studies was: eight studies in American people, 8; in European people, 15 in Asians, and one in Africans. The pooled prevalence for viral and bacterial infections w ere 53.72 (95 CI 38.1�69.1) and 31.21 (95 CI 19.9�43.7), respectively. The highest and lowest prevalence of viral infections was HSV (77.7 95 CI 38.48�99.32), EBV (72.02, 95 CI 44.65�90.79) and Influenza A (7.3, 95 CI 2.66�42.45), respectively. Whereas the highest and lowest prevalence in bacterial infections were related to Streptococcus sp. (99.49, 95 CI 96.44�99.9) and Raoultella (1.2, 95 CI 0.2�3.08), respectively. Conclusions: The results of this review were confirmed that the presence of viral and bacterial infections are the risk factors in the pathogenesis of IPF. In further analyses, which have never been shown in the previous studies, we revealed the geographic variations in the association strengths and emphasized other methodological parameters (e.g., detection method). Also, our study supports the hypothesis that respiratory infection could play a key role in the pathogenesis of IP. © 2021, The Author(s)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research